Taylor, Hugh S.

Supplementary fig. 1: Showing HOXA11-AS-pcDNA3.1(+) plasmid map (7039 bp) containing HOXA11-AS gene (1640 bp)

Supplementary fig. 1: Showing HOXA11-AS-pcDNA3.1(+) plasmid map (7039 bp) containing HOXA11-AS gene (1640 bp)

Supplementary fig. 2: HOXA11-AS expression levels in COC and progestin subgroups. mRNA levels in ectopic lesions were determined by quantitative RT-qPCR from patients with endometriosis. HOXA11-AS mRNA levels were downregulated in endometri…

Supplementary fig. 2: HOXA11-AS expression levels in COC and progestin subgroups. mRNA levels in ectopic lesions were determined by quantitative RT-qPCR from patients with endometriosis. HOXA11-AS mRNA levels were downregulated in endometri…

Supplementary Material 3

Supplementary Material 3

Abstract Objective To investigate the function of HOXA11-antisense long non-coding RNA (HOXA11-AS) in endometriosis treatment response. Methods Tissue samples (ectopic and eutopic endometrium) were obtained from surgically diagnosed subject…

Abstract Objective To investigate the function of HOXA11-antisense long non-coding RNA (HOXA11-AS) in endometriosis treatment response. Methods Tissue samples (ectopic and eutopic endometrium) were obtained from surgically diagnosed subject…

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

Bazedoxifene (BZA) paired with conjugated estrogens (CE) is the first tissue selective estrogen receptor complex (TSEC) approved by the United States Food and Drug Administration for the treatment of menopausal symptoms. Clinical trials in …

Bazedoxifene (BZA) paired with conjugated estrogens (CE) is the first tissue selective estrogen receptor complex (TSEC) approved by the United States Food and Drug Administration for the treatment of menopausal symptoms. Clinical trials in …

Bazedoxifene (BZA) paired with conjugated estrogens (CE) is the first tissue selective estrogen receptor complex (TSEC) approved by the United States Food and Drug Administration for the treatment of menopausal symptoms. Clinical trials in …

Objectives:The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain.Methods:Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (El…

Objectives:The objective was to evaluate the effects of elagolix on dyspareunia in women with endometriosis-associated pain.Methods:Data were pooled from two similar, randomized, double-blind, placebo-controlled, 6-month phase 3 studies (El…

Supplemental material, Leyland_EMph3_Dysp_appendix_revision_1July2019 for Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain by Nicholas Leyland, Hugh S Taylor,…

Supplemental material, Leyland_EMph3_Dysp_appendix_revision_1July2019 for Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain by Nicholas Leyland, Hugh S Taylor,…

Endometriosis affects approximately 15% of reproductive aged women and is associated with chronic pelvic pain and infertility. However, the molecular mechanisms by which endometriosis impacts fertility are poorly understood. The development…

Endometriosis is found in 5-15% of women of reproductive age and is more frequent in relatives of women with the disease. Activation of KRAS results in de novo endometriosis in mice, however, activating KRAS mutations have not been identifi…